US Patent Issued to Atea Pharmaceuticals on Sept. 29 for "NiRAN interfering drugs for SARS-CoV-2 mutant therapy" (French, American Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,746,251, issued on Sept. 29, was assigned to Atea Pharmaceuticals Inc. (Boston).

"NiRAN interfering drugs for SARS-CoV-2 mutant therapy" was invented by Jean-Pierre Sommadossi (Boston), Kai Lin (Belmont, Mass.), Adel Moussa (Burlington, Mass.), Bruno Canard (Marseilles, France) and Ashleigh Shannon (Marseilles, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltra...